CA3051403C - Compositions for the treatment of rosacea - Google Patents
Compositions for the treatment of rosacea Download PDFInfo
- Publication number
- CA3051403C CA3051403C CA3051403A CA3051403A CA3051403C CA 3051403 C CA3051403 C CA 3051403C CA 3051403 A CA3051403 A CA 3051403A CA 3051403 A CA3051403 A CA 3051403A CA 3051403 C CA3051403 C CA 3051403C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- alcohol
- agent
- benzoyl peroxide
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 200
- 201000004700 rosacea Diseases 0.000 title claims abstract description 47
- 241001303601 Rosacea Species 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims description 33
- 230000000699 topical effect Effects 0.000 claims abstract description 17
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 108
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 97
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 93
- 239000000654 additive Substances 0.000 claims description 61
- 230000000996 additive effect Effects 0.000 claims description 57
- 239000000499 gel Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000007787 solid Substances 0.000 claims description 32
- 238000004090 dissolution Methods 0.000 claims description 27
- 239000013543 active substance Substances 0.000 claims description 24
- 239000000839 emulsion Substances 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000002757 inflammatory effect Effects 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000003094 microcapsule Substances 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 12
- 235000019198 oils Nutrition 0.000 claims description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 11
- 230000003902 lesion Effects 0.000 claims description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 11
- 230000002411 adverse Effects 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000002562 thickening agent Substances 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 9
- 239000004098 Tetracycline Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 150000002191 fatty alcohols Chemical class 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 235000019364 tetracycline Nutrition 0.000 claims description 8
- 150000003522 tetracyclines Chemical class 0.000 claims description 8
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 claims description 8
- 239000004599 antimicrobial Substances 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 229940075529 glyceryl stearate Drugs 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 239000007764 o/w emulsion Substances 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002270 dispersing agent Substances 0.000 claims description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 6
- 239000004584 polyacrylic acid Substances 0.000 claims description 6
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960002180 tetracycline Drugs 0.000 claims description 6
- 229930101283 tetracycline Natural products 0.000 claims description 6
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 5
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 5
- 229960000541 cetyl alcohol Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229940086555 cyclomethicone Drugs 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 5
- -1 hydroxyl methyl Chemical group 0.000 claims description 5
- 229960005280 isotretinoin Drugs 0.000 claims description 5
- 229960002666 1-octacosanol Drugs 0.000 claims description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 claims description 4
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 4
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 claims description 4
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 4
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims description 4
- 229960001445 alitretinoin Drugs 0.000 claims description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 4
- 238000012377 drug delivery Methods 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 235000004626 essential fatty acids Nutrition 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 4
- 239000003349 gelling agent Substances 0.000 claims description 4
- FIPPFBHCBUDBRR-UHFFFAOYSA-N henicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCO FIPPFBHCBUDBRR-UHFFFAOYSA-N 0.000 claims description 4
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 claims description 4
- 229920001519 homopolymer Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 4
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 4
- 230000001333 moisturizer Effects 0.000 claims description 4
- XGFDHKJUZCCPKQ-UHFFFAOYSA-N nonadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 claims description 4
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 claims description 4
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 4
- 230000000149 penetrating effect Effects 0.000 claims description 4
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000003009 skin protective agent Substances 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- 230000000475 sunscreen effect Effects 0.000 claims description 4
- 239000000516 sunscreening agent Substances 0.000 claims description 4
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 claims description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 229920000592 inorganic polymer Polymers 0.000 claims description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 3
- 229960000282 metronidazole Drugs 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
- CFOQKXQWGLAKSK-KTKRTIGZSA-N (13Z)-docosen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCO CFOQKXQWGLAKSK-KTKRTIGZSA-N 0.000 claims description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical group C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 claims description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 2
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 claims description 2
- CFOQKXQWGLAKSK-UHFFFAOYSA-N 13-docosen-1-ol Natural products CCCCCCCCC=CCCCCCCCCCCCCO CFOQKXQWGLAKSK-UHFFFAOYSA-N 0.000 claims description 2
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- DKGXIVRSAKPDHF-UHFFFAOYSA-N 6-chloro-3-methyl-1-phenylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=C(Cl)N1C1=CC=CC=C1 DKGXIVRSAKPDHF-UHFFFAOYSA-N 0.000 claims description 2
- IKYKEVDKGZYRMQ-IUQGRGSQSA-N 9,12,15-Octadecatrien-1-ol Chemical compound CC\C=C\C\C=C\C\C=C\CCCCCCCCO IKYKEVDKGZYRMQ-IUQGRGSQSA-N 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 claims description 2
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000005662 Paraffin oil Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920002396 Polyurea Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 229960005339 acitretin Drugs 0.000 claims description 2
- 229960002916 adapalene Drugs 0.000 claims description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 229960003679 brimonidine Drugs 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 2
- 239000004927 clay Substances 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960002896 clonidine Drugs 0.000 claims description 2
- 239000007957 coemulsifier Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- 229940094522 laponite Drugs 0.000 claims description 2
- JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 claims description 2
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 claims description 2
- 229960002342 mephentermine Drugs 0.000 claims description 2
- RXQCGGRTAILOIN-UHFFFAOYSA-N mephentermine Chemical compound CNC(C)(C)CC1=CC=CC=C1 RXQCGGRTAILOIN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003663 metaraminol Drugs 0.000 claims description 2
- 229960005192 methoxamine Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229960001094 midodrine Drugs 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- 229960005016 naphazoline Drugs 0.000 claims description 2
- 229960002748 norepinephrine Drugs 0.000 claims description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- ALSTYHKOOCGGFT-MDZDMXLPSA-N oleyl alcohol Chemical compound CCCCCCCC\C=C\CCCCCCCCO ALSTYHKOOCGGFT-MDZDMXLPSA-N 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 229960001528 oxymetazoline Drugs 0.000 claims description 2
- LBIYNOAMNIKVKF-FPLPWBNLSA-N palmitoleyl alcohol Chemical compound CCCCCC\C=C/CCCCCCCCO LBIYNOAMNIKVKF-FPLPWBNLSA-N 0.000 claims description 2
- LBIYNOAMNIKVKF-UHFFFAOYSA-N palmitoleyl alcohol Natural products CCCCCCC=CCCCCCCCCO LBIYNOAMNIKVKF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 229960000565 tazarotene Drugs 0.000 claims description 2
- 229960000337 tetryzoline Drugs 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- 229940087291 tridecyl alcohol Drugs 0.000 claims description 2
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 229960000833 xylometazoline Drugs 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 229910044991 metal oxide Inorganic materials 0.000 description 59
- 239000013618 particulate matter Substances 0.000 description 57
- 150000004706 metal oxides Chemical class 0.000 description 54
- 238000000034 method Methods 0.000 description 39
- 238000000576 coating method Methods 0.000 description 30
- 239000000725 suspension Substances 0.000 description 29
- 125000002091 cationic group Chemical group 0.000 description 28
- 239000006185 dispersion Substances 0.000 description 26
- 230000008569 process Effects 0.000 description 26
- 239000011248 coating agent Substances 0.000 description 24
- 239000002245 particle Substances 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000010410 layer Substances 0.000 description 21
- 239000012736 aqueous medium Substances 0.000 description 20
- 239000011162 core material Substances 0.000 description 20
- 239000012071 phase Substances 0.000 description 15
- 230000032683 aging Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 239000007900 aqueous suspension Substances 0.000 description 8
- 239000003093 cationic surfactant Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011247 coating layer Substances 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 229920006317 cationic polymer Polymers 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003945 anionic surfactant Substances 0.000 description 5
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 229920002675 Polyoxyl Polymers 0.000 description 4
- 206010037888 Rash pustular Diseases 0.000 description 4
- 239000004115 Sodium Silicate Substances 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 208000029561 pustule Diseases 0.000 description 4
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 4
- 229910052911 sodium silicate Inorganic materials 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 206010043189 Telangiectasia Diseases 0.000 description 3
- 229920006318 anionic polymer Polymers 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000009056 telangiectasis Diseases 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940059145 benzac Drugs 0.000 description 2
- 229960002788 cetrimonium chloride Drugs 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229920000831 ionic polymer Polymers 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229940044279 neobenz micro Drugs 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 1
- 206010003046 Application site irritation Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193880 Demodex folliculorum Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 208000003493 Rhinophyma Diseases 0.000 description 1
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000012868 active agrochemical ingredient Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940008944 clindamycin topical gel Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2012/050479 WO2014083557A1 (en) | 2012-11-27 | 2012-11-27 | Compositions for the treatment of rosacea |
| WOPCT/IL2012/050479 | 2012-11-27 | ||
| CA2889199A CA2889199C (en) | 2012-11-27 | 2012-11-27 | Compositions for the treatment of rosacea |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2889199A Division CA2889199C (en) | 2012-11-27 | 2012-11-27 | Compositions for the treatment of rosacea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3051403A1 CA3051403A1 (en) | 2014-06-05 |
| CA3051403C true CA3051403C (en) | 2021-07-20 |
Family
ID=47428789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3051403A Active CA3051403C (en) | 2012-11-27 | 2012-11-27 | Compositions for the treatment of rosacea |
| CA2889199A Active CA2889199C (en) | 2012-11-27 | 2012-11-27 | Compositions for the treatment of rosacea |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2889199A Active CA2889199C (en) | 2012-11-27 | 2012-11-27 | Compositions for the treatment of rosacea |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2925296B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6423355B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104853746B (cg-RX-API-DMAC7.html) |
| CA (2) | CA3051403C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2861431T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX376183B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014083557A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017068673A1 (ja) * | 2015-10-21 | 2017-04-27 | マルホ株式会社 | 皮膚用の医薬組成物 |
| EP3426706A1 (en) | 2016-03-08 | 2019-01-16 | Living Proof, Inc. | Long lasting cosmetic compositions |
| JP2020527140A (ja) * | 2017-07-12 | 2020-09-03 | ソル − ゲル テクノロジーズ リミテッド | カプセル化トレチノインを含む組成物 |
| US10987300B2 (en) | 2017-09-13 | 2021-04-27 | Living Proof, Inc. | Long lasting cosmetic compositions |
| EP3681921A2 (en) | 2017-09-13 | 2020-07-22 | Living Proof, Inc. | Color protectant compositions |
| US12029805B2 (en) | 2017-11-20 | 2024-07-09 | Living Proof, Inc. | Properties for achieving long-lasting cosmetic performance |
| EP3784711A1 (en) | 2018-04-27 | 2021-03-03 | Living Proof, Inc. | Long lasting cosmetic compositions |
| EP3586849A1 (en) | 2018-06-29 | 2020-01-01 | Aprofol AG | Folate preparations |
| JP6811213B2 (ja) * | 2018-07-03 | 2021-01-13 | ソル − ゲル テクノロジーズ リミテッド | 酒さの治療のための組成物 |
| CA3130437A1 (en) | 2019-02-19 | 2020-08-27 | Sol-Gel Technologies Ltd. | Method for treatment of rosacea |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10182378T1 (de) * | 2000-04-21 | 2012-02-02 | Sol-Gel Technologies Ltd. | Zusammensetzung mit erhöter Formulationsstabilität und Verabreichung von topischen Wirkstoffen |
| GB0301577D0 (en) * | 2003-01-23 | 2003-02-26 | Edko Pazarlama Tanitim Ltd Sti | Topical pharmaceutical and/or cosmetic dispense systems |
| FR2886850B1 (fr) | 2005-06-10 | 2007-10-05 | Galderma Sa | Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee |
| WO2008057411A1 (en) * | 2006-11-02 | 2008-05-15 | Stiefel Laboratories, Inc. | Kits containing benzoyl peroxide pads and another acne-treating composition, and formulations and methods of use therefor |
| FR2909000B1 (fr) * | 2006-11-28 | 2009-02-06 | Galderma Res & Dev S N C Snc | Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations. |
| FR2910320B1 (fr) * | 2006-12-21 | 2009-02-13 | Galderma Res & Dev S N C Snc | Emulsion comprenant au moins un retinoide et du peroxyde de benzole |
| JP2010517996A (ja) * | 2007-02-01 | 2010-05-27 | ソル − ゲル テクノロジーズ リミテッド | 過酸化物及びレチノイドを含む局所適用用組成物 |
| EP2545776A3 (en) * | 2007-02-01 | 2014-12-24 | Sol-Gel Technologies Ltd. | Method for preparing particles comprising metal oxide coating and particles with metal oxide coating |
| CN101969923A (zh) * | 2007-11-30 | 2011-02-09 | 盖尔德马研究及发展公司 | 含有至少一种萘甲酸衍生物、过氧化苯甲酰和至少一种成膜剂的组合物、它们的制备方法及其用途 |
| AU2009255679B2 (en) * | 2008-06-05 | 2015-04-09 | Dow Pharmaceutical Sciences, Inc. | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
| EP2307129A2 (en) * | 2008-07-31 | 2011-04-13 | Sol-Gel Technologies Ltd. | Microcapsules comprising active ingredients and a metal oxide shell, a method for their preparation and uses thereof |
| JP2012514593A (ja) * | 2009-01-05 | 2012-06-28 | ゾル−ゲル テクノロジー リミテッド | 被覆した活性剤を含む局所組成物 |
| RU2572693C2 (ru) * | 2009-10-21 | 2016-01-20 | Дау Фармасьютикал Сайенсиз, Инк. | Способ смачивания порошка, содержащего пероксид бензоила |
| ES2611499T3 (es) * | 2009-12-31 | 2017-05-09 | Sol-Gel Technologies Ltd. | Microcápsulas de núcleo estabilizado, procedimiento para su preparación y usos de las mismas |
| US20120064135A1 (en) * | 2010-09-15 | 2012-03-15 | Norac Pharma | Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof |
-
2012
- 2012-11-27 ES ES12805780T patent/ES2861431T3/es active Active
- 2012-11-27 JP JP2015543565A patent/JP6423355B2/ja not_active Expired - Fee Related
- 2012-11-27 CA CA3051403A patent/CA3051403C/en active Active
- 2012-11-27 EP EP12805780.9A patent/EP2925296B1/en active Active
- 2012-11-27 MX MX2015005515A patent/MX376183B/es active IP Right Grant
- 2012-11-27 CN CN201280077293.2A patent/CN104853746B/zh active Active
- 2012-11-27 WO PCT/IL2012/050479 patent/WO2014083557A1/en not_active Ceased
- 2012-11-27 CN CN201810145665.XA patent/CN108159425A/zh active Pending
- 2012-11-27 CA CA2889199A patent/CA2889199C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX376183B (es) | 2025-03-07 |
| CN104853746B (zh) | 2018-02-23 |
| EP2925296B1 (en) | 2021-01-06 |
| JP2016501205A (ja) | 2016-01-18 |
| JP6423355B2 (ja) | 2018-11-14 |
| MX2015005515A (es) | 2015-07-17 |
| CA3051403A1 (en) | 2014-06-05 |
| ES2861431T3 (es) | 2021-10-06 |
| CA2889199A1 (en) | 2014-06-05 |
| CN104853746A (zh) | 2015-08-19 |
| WO2014083557A1 (en) | 2014-06-05 |
| CN108159425A (zh) | 2018-06-15 |
| EP2925296A1 (en) | 2015-10-07 |
| CA2889199C (en) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200405665A1 (en) | Methods for the treatment of rosacea | |
| CA3051403C (en) | Compositions for the treatment of rosacea | |
| EP2109445B1 (en) | Compositions for topical application comprising a peroxide and retinoid | |
| JP2015518031A (ja) | レチノイド含有マイクロカプセル、その調製方法、及び当該レチノイド含有マイクロカプセルを含む医薬組成物 | |
| US20210169841A1 (en) | Method for treatment of rosacea in patients aged 65 years and older | |
| JP6788066B2 (ja) | 過酸化ベンゾイルおよびアダパレンを含む局所投与用組成物 | |
| JP6811213B2 (ja) | 酒さの治療のための組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200107 |